• Early detection and accurate diagnosis are essential for optimising clinical management and improving outcomes in patients with amyloidosis
• The National Amyloidosis Centre has a range of advanced diagnostic techniques to confirm the presence of amyloidosis in a person
• Investigations may include SAP scintigraphy, cardiac MRI scans, DPD scans and genetic testing
• Accurate subtyping enables tailored therapeutic strategies, which are key to effective disease management

Speakers

Angelique Smit, Lead Clinical and Research Nurse
Darren Foard, Lead AL Amyloidosis Clinical Nurse Specialist
David Hutt, Lead Nuclear Medicine Technologist
Dr Tamer Rezk, Consultant Nephrologist
Dr Ana Martinez Naharro, Consultant Cardiologist
Dr Dorota Rowczenio, Head of Genetic Service
Emily Dixon, Principal Genetic Counsellor
Professor Philip Hawkins, Consultant Physician; Clinical Director; Founder of NAC

• Early detection and diagnosis are key for improving outcomes in people with amyloidosis
• 3 major types of amyloidosis: TTR amyloidosis, AL amyloidosis and AA amyloidosis
• The NAC processes over 2500 cases of amyloidosis per year and offers a holistic approach to managing amyloidosis including genetic counselling

Speakers

Angelique Smit, Lead Clinical and Research Nurse
Professor Philip Hawkins, Consultant Physician; Clinical Director; Founder of NAC
Professor Ashu Wechalekar, Laboratory Director and Consultant Haematologist
Janet Gilbertson, Head of Histology; Proteomic Service and Laboratory Manager
Dr Yousuf Razvi, Clinical Research Fellow
Professor Marianna Fontana, Deputy Clinical and Research Lead
Dr Carol Whelan, Consultant Cardiologist
Professor Julian Gillmore, NAC Research Lead
Emily Dixon, Principal Genetic Counsellor
Dr Tamer Rezk, Consultant Nephrologist
Christine Chiti, Clinical TTR Nurse Specialist

Speakers:

Professor Julian Gillmore, Centre Head, Centre for Amyloidosis, University College London, The National Amyloidosis Centre, London

Dr Tamer Rezk, Academic Consultant Nephrologist, University College London, London

View the BJC Amyloidosis Hub

Speakers:

Dr Sarah Birkhoelzer, Heart Failure and Imaging Fellow, University Hospitals Dorset NHS Foundation Trust, Bournemouth

Professor Marianna Fontana, Deputy Clinical and Research Lead, National Amyloidosis Centre, London

View the BJC Amyloidosis Hub

Dr Holly Morgan, Clinical Lecturer and Interventional Cardiology Fellow, King’s College London
Dr Julia Kenkre, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Trust

Learning objectives

• Why Lp(a) is gaining clinical importance, and how elevated Lp(a) levels can influence cardiovascular risk
• Best practice for measuring Lp(a) levels including who should be tested and how results can guide management strategies

Podcast

To listen to the podcast version, click here

• Peripheral arterial and aortic disease
• Elevated blood pressure and hypertension
• Chronic coronary syndromes
• Atrial fibrillation

Speakers

Dr Paul Foley, Cardiologist, The Great Western Hospitals NHS Foundation Trust
Professor Terry McCormack, Professor of Primary Care Cardiovascular Medicine; Immediate Past President of British and Irish Hypertension Society; Institute of Clinical and Applied Health Research, Hull York Medical School; Whitby Group Practice, Whitby

• Structural heart disease
• Atrial fibrillation
• Heart failure management

Speakers

Dr Sarah Birkhoelzer, Cardiology Registrar and Clinical Research Fellow, Oxford
Dr Aaron Henry, NIHR Academic Clinical Fellow, Oxford; Cardiology Research Fellow, Jersey